Immunicon Achieves Endpoint in its Pivotal Clinical Trial in Metastatic Androgen-Independent Prostate Cancer.
Business Wire (January 18, 2007)
Permanent Link:
http://vlex.com/vid/immunicon-endpoint-metastatic-androgen-55087572
Id. vLex: VLEX-55087572
Acceda a este documento
y pruebe vLex GRATIS durante 3 días
Immunicon Achieves Endpoint in its Pivotal Clinical Trial in Metastatic Androgen-Independent Prostate Cancer.
HUNTINGDON VALLEY, Pa. -- Immunicon Corporation (NASDAQ-GM:IMMC) announced today that the Company met its primary endpoint associated with its pivotal clinical trial in metastatic androgen-independent prostate cancer. The primary endpoint was that circulating tumor cells (CTC) levels thr...
Try vLex for FREE for 3 days
Access legal information from United States including:
- Constitutions
- Forms and Contracts
- Legal Books and Journals
- Case Law
- News and Business
- Regulations
- U.S. Code
Try vLex without any commitment for 3 days and see why you need it.
3
days of Free Access
If you are already a vLex customer, Access Here
